- Home
- FNGR vs MREO Comparison
FNGR vs MREO Comparison
Compare FNGR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FNGR | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 52.5M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FNGR | MREO |
|---|---|---|
| Price | $0.47 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.4M | ★ 4.4M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,132,261.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.20 |
| 52 Week High | $2.35 | $2.94 |
Technical Indicators
Market Signals| Indicator | FNGR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 54.48 |
| Support Level | N/A | $0.30 |
| Resistance Level | $1.12 | $0.36 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 7.34 | 42.20 |
Price Performance
Historical ComparisonAbout FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).